5 on the Fly
As the European general aviation sector witnesses a robust increase in traffic, the need for tailored avionics solutions has become critical. uAvionix steps into this pivotal moment with bespoke products for the European and UK markets, promising to address the unique requirements of this diverse aviation landscape. What does uAvionix’s entry into the European avionics…
Latest
5 on the Fly
AEA 2024: Software Updates for the Connected Cockpit
The intersection of aviation and technology has never been more exciting than at AEA 2024, where the concept of a connected cockpit takes a groundbreaking turn. With a 30% increase in general aviation traffic relying on legacy systems, the stakes for a cohesive digital transition are high. This technological leap promises to redefine the…
Latest
Analyzing the Suppressive TME in In Vitro Based Assays
In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…
Targeting T Cells Within the Cancer Immunity Cycle
As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…
Inside Oncology Drug Development: Overcoming Resistance with Science
In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…
